MHRA and NICE invite early adopters to trial accelerated aligned pathway – six months ahead of schedule

Friday 10 October, 2025
Pharmaceutical companies who make qualifying medicines can now take advantage of a streamlined approvals pathway for medicines much earlier than anticipated. Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them sooner.The Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) are now offering some pharmaceutical companies early access to the aligned pathway six months earlier than projected…
Read More